TAS 115

Drug Profile

TAS 115

Alternative Names: Dual MET/VEGFR inhibitor - Taiho Pharmaceutical; TAS-115

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hepatocyte growth factor inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2018 Taiho Pharmaceutical plans a phase II trial for Idiopathic pulmonary fibrosis in Japan , (JapicCTI183898)
  • 08 Sep 2017 Interim adverse events and efficacy data from a phase I trial in Prostate cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Dec 2016 Taiho Pharmaceutical plans a phase II trial for Prostate cancer in Japan (JapicCTI-163448)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top